{"success":true,"data":{"pressRelease":{"id":"126966","rtpr_id":"nBw2XwQ5Ka","ticker":"HIND","exchange":"NASDAQ","all_tickers":["HIND"],"title":"Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet","author":"Business Wire","published_at":"2026-08-25T12:00:02.112Z","article_body":"Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement\nof Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet\n\nVyome Holdings, Inc. (Nasdaq: HIND, “Vyome”), a clinical-stage\nbiopharmaceutical company focused on immuno-inflammatory and rare disease\nconditions, today reports financial results for the second quarter ended June\n30, 2026, and provides a corporate update.\n\nKrishna Gupta, Chairman, Vyome Holdings, said, “Vyome continues to execute\nwith focus and discipline across its development programs while maintaining a\nmethodical and conservative approach to capital allocation. During the\nquarter, we advanced our lead VT-1953 program, broadened our pipeline through\nthe Impetis agreement and continued to strengthen our intellectual property\nportfolio. With a strong balance sheet and disciplined capital structure, we\nbelieve Vyome is well positioned to pursue its development priorities and\ncreate long-term shareholder value.”\n\nVenkat Nelabhotla, Vyome President and Chief Executive Officer, stated,\n“VT-1953 remains our lead priority. The Phase 2 data presented this year\ndemonstrated statistically significant improvements in malodor, the\npatient-reported impact of malodor on daily life, and lesion pain, with no\ntreatment-emergent adverse events reported. In March 2026, we submitted a\npre-IND briefing package to the FDA that included our proposed pivotal\nclinical study strategy for the treatment of malodor and other symptoms\nassociated with malignant fungating wounds. During the second quarter of 2026,\nthe Company received the FDA’s written response on the proposed clinical\ndevelopment program. The Company is incorporating the FDA’s feedback,\npreparing the appropriate supporting package, and plans to continue its\nengagement with the FDA through a Type C meeting to further advance the\nclinical development program.\n\n“At the same time, we are selectively building additional opportunities\naround our core immuno-inflammatory strategy. Our agreement with Impetis adds\ntwo selective JAK inhibitor assets and provides potential access to important\nautoimmune and inflammatory disease categories. We intend to advance these\nopportunities in a disciplined manner with non-dilutive methods while keeping\nVT-1953 as our primary development focus. Importantly, we continue to maintain\na clean capital structure with no debt, no preferred stock, and no toxic\nfinancing instruments. We believe this combination of focused clinical\nexecution, pipeline optionality, and financial discipline provides a strong\nfoundation for long-term shareholder value,” concluded Mr. Nelabhotla.\n\nSecond Quarter 2026 and Recent Corporate Highlights\n\n\n * In March 2026, submitted a pre-IND briefing package to the FDA including the\nproposed pivotal clinical study strategy for VT-1953; received the FDA’s\nwritten response on the proposed clinical development program during the\nsecond quarter; is incorporating the FDA’s feedback, preparing the\nappropriate supporting package, and plans to continue its engagement with the\nFDA through a Type C meeting to further advance the clinical development\nprogram\n\n * Presented Phase 2 clinical data on lead candidate VT-1953 topical gel for\ntreatment of malignant fungating wounds (MFW) at the American Association for\nCancer Research (AACR), including:\n\n\n* Statistically significant reduction in malodor (primary endpoint)\n\n * Statistically significant improvement in patient-reported impact of malodor on\ndaily life\n\n * Statistically significant improvement in lesion pain\n\n * No treatment-emergent adverse events\n\n\n\n\n\n * Signed agreement with Impetis Biosciences Limited (“Impetis’) to\nin-license two selective JAK inhibitor assets designed for higher selectivity\nto potentially treat autoimmune and inflammatory conditions\n\n\n * Received a granted Chinese patent covering formulation and therapeutic use\nclaims related to VB-1953 topical gel program for treating inflammatory acne\n\nFinancial Results for the Quarter Ended June 30, 2026\n\n\n * Cash and cash equivalents were approximately $7.9 million as of June 30, 2026,\ncompared with approximately $5.0 million as of December 31, 2025\n\n\n * Total current assets were approximately $8.2 million as of June 30, 2026\n\n\n * Total stockholders’ equity was approximately $7.3 million as of June 30,\n2026\n\n\n * Total operating expenses for the quarter ended June 30, 2026, were\napproximately $874,000, including approximately $507,000 in research and\ndevelopment expenses and approximately $365,000 in selling, general, and\nadministrative expenses\n\n\n * Net loss attributable to common shareholders for the quarter ended June 30,\n2026, was approximately $720,000, or approximately $0.10 per basic and diluted\nshare\n\nComplete financial results can be found in the Company’s recent Quarterly\nReport on Form 10-Q\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.sec.gov%2Fix%3Fdoc%3D%2FArchives%2Fedgar%2Fdata%2F0001427570%2F000121390026088402%2Fea0300868-10q_vyome.htm&esheet=54593844&newsitemid=20260825277204&lan=en-US&anchor=Company%26%238217%3Bs+recent+Quarterly+Report+on+Form+10-Q&index=1&md5=47bd919d1766b79e707f16652c665021)\navailable at sec.gov.\n\nAbout Vyome Holdings, Inc.:\n\nVyome is building the world’s premier platform spanning the US-India\ninnovation corridor. Vyome’s immediate focus is on leveraging its\nclinical-stage assets to transform the lives of patients with\nimmuno-inflammatory conditions. By applying groundbreaking science and its\nunique positioning, Vyome seeks to deliver lasting value to shareholders in a\nhyper cost-efficient manner while upholding global standards of quality and\nsafety.\n\nTo learn more, please visit www.vyometx.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.vyometx.com&esheet=54593844&newsitemid=20260825277204&lan=en-US&anchor=www.vyometx.com&index=2&md5=bf499dce00671c28bca5bf4cc35f58e3)\n\nForward-Looking Statements\n\nCertain statements made in this press release are “forward-looking\nstatements” within the meaning of the “safe harbor” provisions of the\nPrivate Securities Litigation Reform Act of 1995. Forward-looking statements\nmay be identified by the use of words such as “target,” “believe,”\n“expect,” “will,” “shall,” “may,” “anticipate,”\n“estimate,” “would,” “positioned,” “future,” “forecast,”\n“intend,” “plan,” “project,” “outlook,” and other similar\nexpressions that predict or indicate future events or trends or that are not\nstatements of historical matters. Such statements include, but are not limited\nto, statements contained in this press release relating to Vyome’s business\nstrategy, Vyome’s clinical development plans and expected timelines, the\nexpected therapeutic potential of Vyome’s product candidates and pipeline\nassets, Vyome’s intellectual property strategy, Vyome’s future operating\nresults, and Vyome’s liquidity and capital resources outlook.\nForward-looking statements are based on Vyome’s current expectations and\nassumptions regarding Vyome’s business, the economy, and other future\nconditions. Because forward-looking statements relate to the future, they are\nsubject to inherent uncertainties, risks, and changes in circumstances that\nare difficult to predict. Vyome’s actual results may differ materially from\nthose contemplated by the forward-looking statements. They are neither\nstatements of historical fact nor guarantees of assurance of future\nperformance. Vyome cautions you, therefore, against relying on any of these\nforward-looking statements. Important factors that could cause actual results\nto differ materially from those in the forward-looking statements include,\nwithout limitation, Vyome’s ability to raise capital to fund continuing\noperations; the timing and outcome of Vyome’s interactions with the FDA; our\nability to successfully design, initiate, enroll, and complete clinical\ntrials; our ability to protect Vyome’s intellectual property rights; the\nimpact of any infringement actions or other litigation brought against Vyome;\ncompetition from other providers and products; Vyome’s ability to develop\nand commercialize products and services; changes in government regulation; and\nother factors relating to Vyome’s industry, operations and results of\noperations described in Vyome’s Annual Report on Form 10-K for the year\nended December 31, 2025, our Quarterly Reports on Form 10-Q, our Current\nReports on Form 8-K and subsequent filings with the SEC. Actual results may\ndiffer significantly from those anticipated, believed, estimated, expected,\nintended, or planned. Factors or events that could cause Vyome’s actual\nresults to differ may emerge from time to time, and it is not possible for\nVyome to predict all of them. Vyome cannot guarantee future results, levels of\nactivity, performance, or achievements. Vyome assumes no obligation to update\nany forward-looking statements in order to reflect any event or circumstance\nthat may arise after the date of this release, except as may be required under\napplicable securities law.\n SUMMARY FINANCIAL STATEMENTS                                                                \n \n                                                                                           \n \nSUMMARY OF CONDENSED CONSOLIDATED BALANCE SHEETS AS OF                                     \n                                               June 30, 2026           December 31, 2025     \n                                                                                             \n Cash and cash equivalents                     $        7,887,510      $          4,982,333  \n Other current assets                                   265,843                   455,988    \n Long term assets                                       1,023,009                 1,058,856  \n Total assets                                  $        9,176,362      $          6,497,177  \n                                                                                             \n Liabilities                                   $        1,864,656      $          2,735,160  \n Total Stockholders’ equity (deficit)                   7,311,706                 3,762,017  \n Total liabilities and stockholders’ equity    $        9,176,362      $          6,497,177  \n\n\n \n SUMMARY OF CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS                                  \n                                   Six months ended                Six months ended          \n                                   \nJune 30, 2026                  \nJune 30, 2025            \n                                                                   \n                         \n                                                                   \n                         \n Revenues                          $       58,546                  $       248,535           \n Cost of goods sold                        (30,243     )                   (69,881   )       \n                                                                                             \n Gross profit                              28,303                          178,654           \n                                                                                             \n Operating expenses                        2,020,809                       701,839           \n Operating loss                            (1,992,506  )                   (523,185  )       \n                                                                                             \n Interest and other expenses, net          287,302                         (79,547   )       \n                                                                                             \n Net loss                          $       (1,705,204  )           $       (602,732  )       \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260825277204/en/\n(https://www.businesswire.com/news/home/20260825277204/en/)\n\nMedia:
\n\nir@vyometx.com (mailto:ir@vyometx.com)\n\nVisit us on social media:\n\nFacebook \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2Fvyometx%2F&esheet=54593844&newsitemid=20260825277204&lan=en-US&anchor=Facebook&index=3&md5=42d7221f1191ade9bb1428534590c180)\n\nX \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2FVyomeInc&esheet=54593844&newsitemid=20260825277204&lan=en-US&anchor=X&index=4&md5=78f8263c6dac8d92b9ab3c3a1d33b23a)\n\nLinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fvyome-holdings%2F&esheet=54593844&newsitemid=20260825277204&lan=en-US&anchor=LinkedIn&index=5&md5=3cdc1672f7503eea278b7e9a1cfa5acb)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw2XwQ5Ka","title":"Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet","author":"Business Wire","ticker":"HIND","created":"2026-08-25T12:00:02.112Z","tickers":["HIND"],"exchange":"NASDAQ","article_body":"Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement\nof Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet\n\nVyome Holdings, Inc. (Nasdaq: HIND, “Vyome”), a clinical-stage\nbiopharmaceutical company focused on immuno-inflammatory and rare disease\nconditions, today reports financial results for the second quarter ended June\n30, 2026, and provides a corporate update.\n\nKrishna Gupta, Chairman, Vyome Holdings, said, “Vyome continues to execute\nwith focus and discipline across its development programs while maintaining a\nmethodical and conservative approach to capital allocation. During the\nquarter, we advanced our lead VT-1953 program, broadened our pipeline through\nthe Impetis agreement and continued to strengthen our intellectual property\nportfolio. With a strong balance sheet and disciplined capital structure, we\nbelieve Vyome is well positioned to pursue its development priorities and\ncreate long-term shareholder value.”\n\nVenkat Nelabhotla, Vyome President and Chief Executive Officer, stated,\n“VT-1953 remains our lead priority. The Phase 2 data presented this year\ndemonstrated statistically significant improvements in malodor, the\npatient-reported impact of malodor on daily life, and lesion pain, with no\ntreatment-emergent adverse events reported. In March 2026, we submitted a\npre-IND briefing package to the FDA that included our proposed pivotal\nclinical study strategy for the treatment of malodor and other symptoms\nassociated with malignant fungating wounds. During the second quarter of 2026,\nthe Company received the FDA’s written response on the proposed clinical\ndevelopment program. The Company is incorporating the FDA’s feedback,\npreparing the appropriate supporting package, and plans to continue its\nengagement with the FDA through a Type C meeting to further advance the\nclinical development program.\n\n“At the same time, we are selectively building additional opportunities\naround our core immuno-inflammatory strategy. Our agreement with Impetis adds\ntwo selective JAK inhibitor assets and provides potential access to important\nautoimmune and inflammatory disease categories. We intend to advance these\nopportunities in a disciplined manner with non-dilutive methods while keeping\nVT-1953 as our primary development focus. Importantly, we continue to maintain\na clean capital structure with no debt, no preferred stock, and no toxic\nfinancing instruments. We believe this combination of focused clinical\nexecution, pipeline optionality, and financial discipline provides a strong\nfoundation for long-term shareholder value,” concluded Mr. Nelabhotla.\n\nSecond Quarter 2026 and Recent Corporate Highlights\n\n\n * In March 2026, submitted a pre-IND briefing package to the FDA including the\nproposed pivotal clinical study strategy for VT-1953; received the FDA’s\nwritten response on the proposed clinical development program during the\nsecond quarter; is incorporating the FDA’s feedback, preparing the\nappropriate supporting package, and plans to continue its engagement with the\nFDA through a Type C meeting to further advance the clinical development\nprogram\n\n * Presented Phase 2 clinical data on lead candidate VT-1953 topical gel for\ntreatment of malignant fungating wounds (MFW) at the American Association for\nCancer Research (AACR), including:\n\n\n* Statistically significant reduction in malodor (primary endpoint)\n\n * Statistically significant improvement in patient-reported impact of malodor on\ndaily life\n\n * Statistically significant improvement in lesion pain\n\n * No treatment-emergent adverse events\n\n\n\n\n\n * Signed agreement with Impetis Biosciences Limited (“Impetis’) to\nin-license two selective JAK inhibitor assets designed for higher selectivity\nto potentially treat autoimmune and inflammatory conditions\n\n\n * Received a granted Chinese patent covering formulation and therapeutic use\nclaims related to VB-1953 topical gel program for treating inflammatory acne\n\nFinancial Results for the Quarter Ended June 30, 2026\n\n\n * Cash and cash equivalents were approximately $7.9 million as of June 30, 2026,\ncompared with approximately $5.0 million as of December 31, 2025\n\n\n * Total current assets were approximately $8.2 million as of June 30, 2026\n\n\n * Total stockholders’ equity was approximately $7.3 million as of June 30,\n2026\n\n\n * Total operating expenses for the quarter ended June 30, 2026, were\napproximately $874,000, including approximately $507,000 in research and\ndevelopment expenses and approximately $365,000 in selling, general, and\nadministrative expenses\n\n\n * Net loss attributable to common shareholders for the quarter ended June 30,\n2026, was approximately $720,000, or approximately $0.10 per basic and diluted\nshare\n\nComplete financial results can be found in the Company’s recent Quarterly\nReport on Form 10-Q\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.sec.gov%2Fix%3Fdoc%3D%2FArchives%2Fedgar%2Fdata%2F0001427570%2F000121390026088402%2Fea0300868-10q_vyome.htm&esheet=54593844&newsitemid=20260825277204&lan=en-US&anchor=Company%26%238217%3Bs+recent+Quarterly+Report+on+Form+10-Q&index=1&md5=47bd919d1766b79e707f16652c665021)\navailable at sec.gov.\n\nAbout Vyome Holdings, Inc.:\n\nVyome is building the world’s premier platform spanning the US-India\ninnovation corridor. Vyome’s immediate focus is on leveraging its\nclinical-stage assets to transform the lives of patients with\nimmuno-inflammatory conditions. By applying groundbreaking science and its\nunique positioning, Vyome seeks to deliver lasting value to shareholders in a\nhyper cost-efficient manner while upholding global standards of quality and\nsafety.\n\nTo learn more, please visit www.vyometx.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.vyometx.com&esheet=54593844&newsitemid=20260825277204&lan=en-US&anchor=www.vyometx.com&index=2&md5=bf499dce00671c28bca5bf4cc35f58e3)\n\nForward-Looking Statements\n\nCertain statements made in this press release are “forward-looking\nstatements” within the meaning of the “safe harbor” provisions of the\nPrivate Securities Litigation Reform Act of 1995. Forward-looking statements\nmay be identified by the use of words such as “target,” “believe,”\n“expect,” “will,” “shall,” “may,” “anticipate,”\n“estimate,” “would,” “positioned,” “future,” “forecast,”\n“intend,” “plan,” “project,” “outlook,” and other similar\nexpressions that predict or indicate future events or trends or that are not\nstatements of historical matters. Such statements include, but are not limited\nto, statements contained in this press release relating to Vyome’s business\nstrategy, Vyome’s clinical development plans and expected timelines, the\nexpected therapeutic potential of Vyome’s product candidates and pipeline\nassets, Vyome’s intellectual property strategy, Vyome’s future operating\nresults, and Vyome’s liquidity and capital resources outlook.\nForward-looking statements are based on Vyome’s current expectations and\nassumptions regarding Vyome’s business, the economy, and other future\nconditions. Because forward-looking statements relate to the future, they are\nsubject to inherent uncertainties, risks, and changes in circumstances that\nare difficult to predict. Vyome’s actual results may differ materially from\nthose contemplated by the forward-looking statements. They are neither\nstatements of historical fact nor guarantees of assurance of future\nperformance. Vyome cautions you, therefore, against relying on any of these\nforward-looking statements. Important factors that could cause actual results\nto differ materially from those in the forward-looking statements include,\nwithout limitation, Vyome’s ability to raise capital to fund continuing\noperations; the timing and outcome of Vyome’s interactions with the FDA; our\nability to successfully design, initiate, enroll, and complete clinical\ntrials; our ability to protect Vyome’s intellectual property rights; the\nimpact of any infringement actions or other litigation brought against Vyome;\ncompetition from other providers and products; Vyome’s ability to develop\nand commercialize products and services; changes in government regulation; and\nother factors relating to Vyome’s industry, operations and results of\noperations described in Vyome’s Annual Report on Form 10-K for the year\nended December 31, 2025, our Quarterly Reports on Form 10-Q, our Current\nReports on Form 8-K and subsequent filings with the SEC. Actual results may\ndiffer significantly from those anticipated, believed, estimated, expected,\nintended, or planned. Factors or events that could cause Vyome’s actual\nresults to differ may emerge from time to time, and it is not possible for\nVyome to predict all of them. Vyome cannot guarantee future results, levels of\nactivity, performance, or achievements. Vyome assumes no obligation to update\nany forward-looking statements in order to reflect any event or circumstance\nthat may arise after the date of this release, except as may be required under\napplicable securities law.\n SUMMARY FINANCIAL STATEMENTS                                                                \n \n                                                                                           \n \nSUMMARY OF CONDENSED CONSOLIDATED BALANCE SHEETS AS OF                                     \n                                               June 30, 2026           December 31, 2025     \n                                                                                             \n Cash and cash equivalents                     $        7,887,510      $          4,982,333  \n Other current assets                                   265,843                   455,988    \n Long term assets                                       1,023,009                 1,058,856  \n Total assets                                  $        9,176,362      $          6,497,177  \n                                                                                             \n Liabilities                                   $        1,864,656      $          2,735,160  \n Total Stockholders’ equity (deficit)                   7,311,706                 3,762,017  \n Total liabilities and stockholders’ equity    $        9,176,362      $          6,497,177  \n\n\n \n SUMMARY OF CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS                                  \n                                   Six months ended                Six months ended          \n                                   \nJune 30, 2026                  \nJune 30, 2025            \n                                                                   \n                         \n                                                                   \n                         \n Revenues                          $       58,546                  $       248,535           \n Cost of goods sold                        (30,243     )                   (69,881   )       \n                                                                                             \n Gross profit                              28,303                          178,654           \n                                                                                             \n Operating expenses                        2,020,809                       701,839           \n Operating loss                            (1,992,506  )                   (523,185  )       \n                                                                                             \n Interest and other expenses, net          287,302                         (79,547   )       \n                                                                                             \n Net loss                          $       (1,705,204  )           $       (602,732  )       \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260825277204/en/\n(https://www.businesswire.com/news/home/20260825277204/en/)\n\nMedia:
\n\nir@vyometx.com (mailto:ir@vyometx.com)\n\nVisit us on social media:\n\nFacebook \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2Fvyometx%2F&esheet=54593844&newsitemid=20260825277204&lan=en-US&anchor=Facebook&index=3&md5=42d7221f1191ade9bb1428534590c180)\n\nX \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2FVyomeInc&esheet=54593844&newsitemid=20260825277204&lan=en-US&anchor=X&index=4&md5=78f8263c6dac8d92b9ab3c3a1d33b23a)\n\nLinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fvyome-holdings%2F&esheet=54593844&newsitemid=20260825277204&lan=en-US&anchor=LinkedIn&index=5&md5=3cdc1672f7503eea278b7e9a1cfa5acb)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-08-25T12:00:03.225820107Z","server_sent_at_ms":1787659203225},"received_at":"2026-08-25T12:00:03.274Z","source_url":"https://www.businesswire.com/news/home/20260825277204/en/"},"analysis":{"id":"115895","press_release_id":"126966","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"Vyome reported Q2 2026 financial results with cash increasing to $7.9 million from $5.0 million at year-end 2025, while operating expenses remained low at approximately $874,000 for the quarter.\n\nOperationally, the company received written FDA feedback on its proposed pivotal clinical study strategy for lead candidate VT-1953 and plans to advance the program through a Type C meeting following positive Phase 2 data.\n\nThe pipeline expanded through an agreement with Impetis Biosciences to in-license two selective JAK inhibitor assets, complemented by the granting of a Chinese patent for the VB-1953 topical gel program.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Strong balance sheet and FDA engagement on VT-1953 support steady development progress."},"keyFigures":{"customDimensions":{"net_loss":720000,"rd_expenses":507000,"sga_expenses":365000,"six_month_revenue":58546,"operating_expenses":874000,"cash_and_equivalents":7887510}},"quotedText":"With a strong balance sheet and disciplined capital structure, we believe Vyome is well positioned to pursue its development priorities and create long-term shareholder value.","namedEntities":{"people":[{"name":"Krishna Gupta","role":"Chairman"},{"name":"Venkat Nelabhotla","role":"President and Chief Executive Officer"}],"products":["VT-1953","VB-1953","JAK inhibitor assets"],"companies":[{"name":"Vyome Holdings, Inc.","ticker":"HIND"},{"name":"Impetis Biosciences Limited","relationship":"partner/licensor"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"approximately $7.9 million","context":"Cash and cash equivalents as of June 30, 2026"},{"amount":"approximately $5.0 million","context":"Cash and cash equivalents as of December 31, 2025"},{"amount":"approximately $8.2 million","context":"Total current assets as of June 30, 2026"},{"amount":"approximately $7.3 million","context":"Total stockholders’ equity as of June 30, 2026"},{"amount":"approximately $874,000","context":"Total operating expenses for Q2 2026"},{"amount":"approximately $507,000","context":"Research and development expenses for Q2 2026"},{"amount":"approximately $365,000","context":"Selling, general, and administrative expenses for Q2 2026"},{"amount":"approximately $720,000","context":"Net loss attributable to common shareholders for Q2 2026"},{"amount":"approximately $0.10","context":"Net loss per basic and diluted share for Q2 2026"}]},"materialImpact":{"score":3,"reasoning":"Vyome strengthened its balance sheet with cash increasing to $7.9 million and reported meaningful clinical progress, including receiving written FDA feedback for its lead program VT-1953 and in-licensing new JAK inhibitor assets. While the company remains early-stage, the execution on regulatory milestones and non-dilutive pipeline expansion are positive material developments for a micro-cap."},"tickerRelevance":{"others":[],"primary":"HIND"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":["operations_update","partnership"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"earnings_and_operational_update","sectorWeight":"biotech","clinicalDataSignificance":"Phase 2 statistical significance presented"}},"event_type":"earnings","event_type_secondary":["operations_update","partnership"],"sentiment":"bullish","material_impact_score":3,"narrative":"Vyome reported Q2 2026 financial results with cash increasing to $7.9 million from $5.0 million at year-end 2025, while operating expenses remained low at approximately $874,000 for the quarter.\n\nOperationally, the company received written FDA feedback on its proposed pivotal clinical study strategy for lead candidate VT-1953 and plans to advance the program through a Type C meeting following positive Phase 2 data.\n\nThe pipeline expanded through an agreement with Impetis Biosciences to in-license two selective JAK inhibitor assets, complemented by the granting of a Chinese patent for the VB-1953 topical gel program.","key_figures":{"customDimensions":{"net_loss":720000,"rd_expenses":507000,"sga_expenses":365000,"six_month_revenue":58546,"operating_expenses":874000,"cash_and_equivalents":7887510}},"named_entities":{"people":[{"name":"Krishna Gupta","role":"Chairman"},{"name":"Venkat Nelabhotla","role":"President and Chief Executive Officer"}],"products":["VT-1953","VB-1953","JAK inhibitor assets"],"companies":[{"name":"Vyome Holdings, Inc.","ticker":"HIND"},{"name":"Impetis Biosciences Limited","relationship":"partner/licensor"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"approximately $7.9 million","context":"Cash and cash equivalents as of June 30, 2026"},{"amount":"approximately $5.0 million","context":"Cash and cash equivalents as of December 31, 2025"},{"amount":"approximately $8.2 million","context":"Total current assets as of June 30, 2026"},{"amount":"approximately $7.3 million","context":"Total stockholders’ equity as of June 30, 2026"},{"amount":"approximately $874,000","context":"Total operating expenses for Q2 2026"},{"amount":"approximately $507,000","context":"Research and development expenses for Q2 2026"},{"amount":"approximately $365,000","context":"Selling, general, and administrative expenses for Q2 2026"},{"amount":"approximately $720,000","context":"Net loss attributable to common shareholders for Q2 2026"},{"amount":"approximately $0.10","context":"Net loss per basic and diluted share for Q2 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-25T12:56:03.265Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"earnings_and_operational_update","sectorWeight":"biotech","clinicalDataSignificance":"Phase 2 statistical significance presented"}},"durationMs":194473,"modelName":"glm-4.7"}}